DanCann Pharma A/S: Tetra Bio-Pharma Accelerates REBORN1© Trial
COPENHAGEN, Denmark, 13 July 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma”) hereby on behalf of Tetra Bio-Pharma Inc. (“Tetra”), announce that Tetra Bio-Pharma - a leader in cannabinoid-derived drug discovery and development – yesterday announced that the Central Ethics Committee has approved the proposed protocol modifications allowing additional immediate release oral opioids to be used as comparators in the REBORN1© study. Expanding to three (3) immediate release oral opioids will allow for the acceleration of patient enrolment in the REBORN1© trial.DanCann Pharma signed May